$11.41
-0.19 (-1.64%)
Open$11.61
Previous Close$11.60
Day High$11.69
Day Low$11.11
52W High$15.10
52W Low$5.06
Volume—
Avg Volume291.1K
Market Cap164.55M
P/E Ratio—
EPS$-4.59
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+116.4% upside
Current
$11.41
$11.41
Target
$24.69
$24.69
$14.59
$24.69 avg
$25.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.96M | 11.88M | 13.51M |
| Net Income | 575.0K | 486.8K | 473.9K |
| Profit Margin | 4.4% | 4.1% | 3.5% |
| EBITDA | 905.5K | 814.6K | 969.2K |
| Free Cash Flow | 454.1K | 555.8K | 696.0K |
| Rev Growth | -0.8% | +15.7% | +3.2% |
| Debt/Equity | 0.71 | 1.01 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |